Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation

Journal of Immunology

Volumn 195, Issue 5, 2015, Pages 2006-2018

  Golden, Jackelyn B ^a   Groft, Sarah G ^a   Squeri, Michael V ^a   Debanne, Sara M ^a   Ward, Nicole L ^a,b,c   McCormick, Thomas S ^a,b,c   Cooper, Kevin D ^a,b,c,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The Murdough Family Center for Psoriasis   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD14 ANTIGEN; CD16 ANTIGEN; CD18 ANTIGEN; INTERLEUKIN 17; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; ANGIOPOIETIN RECEPTOR; FC RECEPTOR; TRANSCRIPTOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL AGGREGATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SURFACE PROPERTY; ANIMAL; BLOOD; CELL CULTURE; COCULTURE; CONFOCAL MICROSCOPY; DERMATITIS; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; IMMUNOLOGY; KERATINOCYTE; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; YOUNG ADULT;

ADULT; ANIMALS; ANTIGENS, CD14; CELL ADHESION; CELL AGGREGATION; CELLS, CULTURED; CHRONIC DISEASE; COCULTURE TECHNIQUES; DERMATITIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; KERATINOCYTES; MALE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MIDDLE AGED; MONOCYTES; PSORIASIS; RECEPTOR, TIE-2; RECEPTORS, IGG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME; YOUNG ADULT;

EID: 84940116873     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402307     Document Type: Article

References (56)

1. Di Meglio, P., F. Villanova, and F. O. Nestle. 2014. Psoriasis. Cold Spring Harbor Perspect. Med. 4: a015354.
2. Gniadecki, R. 1998. Regulation of keratinocyte proliferation. Gen. Pharmacol. 30: 619-622.
3. Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
4. Gelfand, J. M., R. S. Azfar, and N. N. Mehta. 2010. Psoriasis and cardiovascular risk: strength in numbers. J. Invest. Dermatol. 130: 919-922.
5. Gelfand, J. M., N. N. Mehta, and S. M. Langan. 2011. Psoriasis and cardiovascular risk: strength in numbers, part II. J. Invest. Dermatol. 131: 1007-1010.
6. Mehta, N. N., R. S. Azfar, D. B. Shin, A. L. Neimann, A. B. Troxel, and J. M. Gelfand. 2010. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur. Heart J. 31: 1000-1006.
7. Mehta, N. N., Y. Yu, R. Pinnelas, P. Krishnamoorthy, D. B. Shin, A. B. Troxel, and J. M. Gelfand. 2011. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am. J. Med. 124: 775.e1-6.
8. Mehta, N. N., Y. Yu, B. Saboury, N. Foroughi, P. Krishnamoorthy, A. Raper, A. Baer, J. Antigua, A. S. Van Voorhees, D. A. Torigian, et al. 2011. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch. Dermatol. 147: 1031-1039.
9. Davidovici, B. B., N. Sattar, J. Prinz, L. Puig, P. Emery, J. N. Barker, P. van de Kerkhof, M. Ståhle, F. O. Nestle, G. Girolomoni, and J. G. Krueger. 2010. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J. Invest. Dermatol. 130: 1785-1796.
10. Lu, Y., H. Chen, P. Nikamo, H. Qi Low, C. Helms, M. Seielstad, J. Liu, A. M. Bowcock, M. Stahle, and W. Liao. 2013. Association of cardiovascular and metabolic disease genes with psoriasis. J. Invest. Dermatol. 133: 836-839.
11. Rogacev, K. S., B. Cremers, A. M. Zawada, S. Seiler, N. Binder, P. Ege, G. Große-Dunker, I. Heisel, F. Hornof, J. Jeken, et al. 2012. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J. Am. Coll. Cardiol. 60: 1512-1520.
12. Wrigley, B. J., E. Shantsila, L. D. Tapp, and G. Y. Lip. 2013. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur. J. Clin. Invest. 43: 121-130.
13. Tapp, L. D., E. Shantsila, B. J. Wrigley, B. Pamukcu, and G. Y. Lip. 2012. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J. Thromb. Haemost. 10: 1231-1241.
14. Dopheide, J. F., V. Obst, C. Doppler, M. C. Radmacher, M. Scheer, M. P. Radsak, T. Gori, A. Warnholtz, C. Fottner, A. Daiber, et al. 2012. Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease. Thromb. Haemost. 108: 1198-1207.
15. Funderburg, N. T., D. A. Zidar, C. Shive, A. Lioi, J. Mudd, L. W. Musselwhite, D. I. Simon, M. A. Costa, B. Rodriguez, S. F. Sieg, and M. M. Lederman. 2012. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 120: 4599-4608.
16. Ziegler-Heitbrock, H. W. 1996. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol. Today 17: 424-428.
17. Martinez, F. O. 2009. The transcriptome of human monocyte subsets begins to emerge. J. Biol. 8: 99.
18. Ancuta, P., K. Y. Liu, V. Misra, V. S. Wacleche, A. Gosselin, X. Zhou, and D. Gabuzda. 2009. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 10: 403.
19. Wong, K. L., J. J. Tai, W. C. Wong, H. Han, X. Sem, W. H. Yeap, P. Kourilsky, and S. C. Wong. 2011. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118: e16-e31.
20. Zawada, A. M., K. S. Rogacev, B. Rotter, P. Winter, R. R. Marell, D. Fliser, and G. H. Heine. 2011. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 118: e50-e61.
21. Zawada, A. M., K. S. Rogacev, S. H. Schirmer, M. Sester, M. Böhm, D. Fliser, and G. H. Heine. 2012. Monocyte heterogeneity in human cardiovascular disease. Immunobiology 217: 1273-1284.
22. Ziegler-Heitbrock, L., P. Ancuta, S. Crowe, M. Dalod, V. Grau, D. N. Hart, P. J. Leenen, Y. J. Liu, G. MacPherson, G. J. Randolph, et al. 2010. Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74-e80.
23. Chiu, Y. G., T. Shao, C. Feng, K. A. Mensah, M. Thullen, E. M. Schwarz, and C. T. Ritchlin. 2010. CD16 (FcRgIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res. Ther. 12: R14.
24. Brunner, P. M., F. Koszik, B. Reininger, M. L. Kalb, W. Bauer, and G. Stingl. 2013. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo- LacNac (slan)+ dendritic cells and macrophages. J. Allergy Clin. Immunol. 132: 1184-1193.e8.
25. Passacquale, G., P. Vamadevan, L. Pereira, C. Hamid, V. Corrigall, and A. Ferro. 2011. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 6: e25595.
26. da Costa Martins, P. A., J. M. van Gils, A. Mol, P. L. Hordijk, and J. J. Zwaginga. 2006. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of β1 and β2 integrins. J. Leukoc. Biol. 79: 499-507.
27. Czepluch, F. S., H. Kuschicke, C. Dellas, J. Riggert, G. Hasenfuss, and K. Schafer 2014. Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease. J. Intern. Med. 275: 144-154.
28. Furman, M. I., M. R. Barnard, L. A. Krueger, M. L. Fox, E. A. Shilale, D. M. Lessard, P. Marchese, A. L. Frelinger, III, R. J. Goldberg, and A. D. Michelson. 2001. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J. Am. Coll. Cardiol. 38: 1002-1006.
29. van Gils, J. M., J. J. Zwaginga, and P. L. Hordijk. 2009. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J. Leukoc. Biol. 85: 195-204.
30. Robbins, C. S., A. Chudnovskiy, P. J. Rauch, J. L. Figueiredo, Y. Iwamoto, R. Gorbatov, M. Etzrodt, G. F. Weber, T. Ueno, N. van Rooijen, et al. 2012. Extramedullary hematopoiesis generates Ly-6Chigh monocytes that infiltrate atherosclerotic lesions. Circulation 125: 364-374.
31. Hilgendorf, I., L. M. Gerhardt, T. C. Tan, C. Winter, T. A. Holderried, B. G. Chousterman, Y. Iwamoto, R. Liao, A. Zirlik, M. Scherer-Crosbie, et al. 2014. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ. Res. 114: 1611-1622.
32. Wang, Y., H. Gao, C. M. Loyd, W. Fu, D. Diaconu, S. Liu, K. D. Cooper, T. S. McCormick, D. I. Simon, and N. L. Ward. 2012. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J. Invest. Dermatol. 132: 2067-2075.
33. Hot, A., V. Lenief, and P. Miossec. 2012. Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann. Rheum. Dis. 71: 768-776.
34. Ward, N. L., C. M. Loyd, J. A. Wolfram, D. Diaconu, C. M. Michaels, and T. S. McCormick. 2011. Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br. J. Dermatol. 164: 750-758.
35. Wolfram, J. A., D. Diaconu, D. A. Hatala, J. Rastegar, D. A. Knutsen, A. Lowther, D. Askew, A. C. Gilliam, T. S. McCormick, and N. L. Ward. 2009. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am. J. Pathol. 174: 1443-1458.
36. Heimbeck, I., T. P. Hofer, C. Eder, A. K. Wright, M. Frankenberger, A. Marei, G. Boghdadi, J. Scherberich, and L. Ziegler-Heitbrock. 2010. Standardized single-platform assay for human monocyte subpopulations: Lower CD14+CD16++ monocytes in females. Cytometry A 77: 823-830.
37. Zhou, L. J., and T. F. Tedder. 1996. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA 93: 2588-2592.
38. Dubertret, L., W. Sterry, J. D. Bos, S. Chimenti, S. Shumack, C. G. Larsen, N. H. Shear, and K. A. Papp, CLEAR Multinational Study Group. 2006. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br. J. Dermatol. 155: 170-181.
39. Griffiths, C. E., B. E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, N. Yeilding, C. Guzzo, Y. Xia, B. Zhou, S. Li, et al; ACCEPT Study Group. 2010. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362: 118-128.
40. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
41. Papp, K. A., C. Leonardi, A. Menter, J. P. Ortonne, J. G. Krueger, G. Kricorian, G. Aras, J. Li, C. B. Russell, E. H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-1189.
42. Papp, K. A., R. G. Langley, M. Lebwohl, G. G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M. C. Hsu, Y. Wang, S. Li, et al; PHOENIX 2 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
43. Leonardi, C. L., A. B. Kimball, K. A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L. T. Dooley, and K. B. Gordon, PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
44. Langley, R. G., B. E. Elewski, M. Lebwohl, K. Reich, C. E. Griffiths, K. Papp, L. Puig, H. Nakagawa, L. Spelman, B. Sigurgeirsson, et al; ERASURE Study Group; FIXTURE Study Group. 2014. Secukinumab in plaque psoriasis-results of two phase 3 trials. N. Engl. J. Med. 371: 326-338.
45. Zimmermann, H. W., S. Seidler, J. Nattermann, N. Gassler, C. Hellerbrand, A. Zernecke, J. J. Tischendorf, T. Luedde, R. Weiskirchen, C. Trautwein, and F. Tacke. 2010. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 5: e11049.
46. Hanai, H., T. Iida, K. Takeuchi, F. Watanabe, M. Yamada, M. Kikuyama, Y. Maruyama, Y. Iwaoka, K. Hirayama, S. Nagata, and K. Takai. 2008. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 103: 1210-1216.
47. Shantsila, E., B. Wrigley, L. Tapp, S. Apostolakis, S. Montoro-Garcia, M. T. Drayson, and G. Y. Lip. 2011. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J. Thromb. Haemost. 9: 1056-1066.
48. Woollard, K. J., and F. Geissmann. 2010. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7: 77-86.
49. Libby, P., M. Nahrendorf, M. J. Pittet, and F. K. Swirski. 2008. Diversity of denizens of the atherosclerotic plaque: not all monocytes are created equal. Circulation 117: 3168-3170.
50. Swirski, F. K., P. Libby, E. Aikawa, P. Alcaide, F. W. Luscinskas, R. Weissleder, and M. J. Pittet. 2007. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117: 195-205.
51. Rogacev, K. S., S. Seiler, A. M. Zawada, B. Reichart, E. Herath, D. Roth, C. Ulrich, D. Fliser, and G. H. Heine. 2011. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur. Heart J. 32: 84-92.
52. Rajagopalan, S., X. P. Meng, S. Ramasamy, D. G. Harrison, and Z. S. Galis. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98: 2572-2579.
53. Sconocchia, G., K. Keyvanfar, F. El Ouriaghli, M. Grube, K. Rezvani, H. Fujiwara, J. P. McCoy, Jr., N. Hensel, and A. J. Barrett. 2005. Phenotype and function of a CD56+ peripheral blood monocyte. Leukemia 19: 69-76.
54. Grip, O., A. Bredberg, S. Lindgren, and G. Henriksson. 2007. Increased subpopulations of CD16+ and CD56+ blood monocytes in patients with active Crohn's disease. Inflamm. Bowel Dis. 13: 566-572.
55. Ashlin, T. G., A. P. Kwan, and D. P. Ramji. 2013. Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL- 17. Cytokine 64: 234-242.
56. Sabatine, M. S., L. Ploughman, K. L. Simonsen, O. A. Iakoubova, T. G. Kirchgessner, K. Ranade, Z. Tsuchihashi, K. E. Zerba, D. U. Long, C. H. Tong, et al. 2008. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler. Thromb. Vasc. Biol. 28: 562-567.